Ali Mortazavi CEO of Silence Therapeutics (LSE: SLN) explains how they are able play with gene expressions, for example switching off a cancer gene or another back on and how this fits in everyday life. SLN are now able to offer several products, reducing risk and at low cost.
Ali joined Silence in August 2012 as director of corporate strategy and became Chief Executive in May 2013. He has over 17 years’ experience in the City and financial services, having started his career as a technology analyst at Duncan Lawrie, before moving to Credit Lyonnais Securities. In 2001, he co-founded Evolution Securities and ran the principal trading and market making arm. Ali has extensive experience in small companies and has held significant stakes in UK listed technology/biotech ventures.
There aren't any comments yet.